Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CELECOXIB Cause Product availability issue? 12 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Product availability issue have been filed in association with CELECOXIB (Celecoxib). This represents 0.0% of all adverse event reports for CELECOXIB.

12
Reports of Product availability issue with CELECOXIB
0.0%
of all CELECOXIB reports
2
Deaths
5
Hospitalizations

How Dangerous Is Product availability issue From CELECOXIB?

Of the 12 reports, 2 (16.7%) resulted in death, 5 (41.7%) required hospitalization, and 5 (41.7%) were considered life-threatening.

Is Product availability issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CELECOXIB. However, 12 reports have been filed with the FAERS database.

What Other Side Effects Does CELECOXIB Cause?

Drug ineffective (8,188) Drug hypersensitivity (5,314) Pain (4,248) Rheumatoid arthritis (3,789) Off label use (3,782) Arthralgia (3,766) Nausea (3,497) Fatigue (3,235) Condition aggravated (3,060) Diarrhoea (3,017)

What Other Drugs Cause Product availability issue?

RUXOLITINIB (2,142) LISDEXAMFETAMINE DIMESYLATE (1,530) CERTOLIZUMAB PEGOL (1,381) VEDOLIZUMAB (636) AMPHETAMINE ASPARTATE\AMPHETAMINE\DEXTROAMPHETAMINE SACCHARATE\DEXTROAMPHETAMINE (610) METHYLPHENIDATE (444) SECUKINUMAB (399) BIMEKIZUMAB-BKZX (364) LACOSAMIDE (359) BRIVARACETAM (324)

Which CELECOXIB Alternatives Have Lower Product availability issue Risk?

CELECOXIB vs CELIPROLOL CELECOXIB vs CELLCEPT CELECOXIB vs CEMIPLIMAB CELECOXIB vs CEMIPLIMAB-RWLC CELECOXIB vs CENEGERMIN-BKBJ

Related Pages

CELECOXIB Full Profile All Product availability issue Reports All Drugs Causing Product availability issue CELECOXIB Demographics